Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid BioTechGrid
  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
  • Home
  • Medical Technology
  • After rejection, FDA approves Telix’s Pixclara, the first FET-PET imaging drug for brain cancer

After rejection, FDA approves Telix’s Pixclara, the first FET-PET imaging drug for brain cancer

September 15, 2026Posted inMedical Technology

The FDA has signed off on the first ever glioma drug imaging diagnostic more than a year after it initially rejected the med.

Post navigation

Previous Post
J&J’s Contineum-partnered depression drug flunks another phase 2 test
Next Post
Novo walks away from $285M pact to develop monthly GLP-1 obesity drug with Ascendis

Recent Posts

  • GSK doubles down on Chimagen with $750M multiple myeloma wager
  • Novo walks away from $285M pact to develop monthly GLP-1 obesity drug with Ascendis
  • After rejection, FDA approves Telix’s Pixclara, the first FET-PET imaging drug for brain cancer
  • J&J’s Contineum-partnered depression drug flunks another phase 2 test
  • Ancient Chinese Herbal Formula Decoded: How Danggui Buxue Decoction Fights Chronic Kidney Disease

Archives

  • September 2026
  • August 2026
  • July 2026
  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • March 2024
  • January 2024
  • September 2023

Privacy Policy    Terms

Scroll to Top